

The National Academies of
SCIENCES • ENGINEERING • MEDICINE
HEALTH AND MEDICINE DIVISION
BOARD ON HEALTH SCIENCES POLICY

CLINICAL UTILITY OF TREATING PATIENTS WITH COMPOUNDED
“BIOIDENTICAL HORMONE REPLACEMENT THERAPY”

Open Session Meeting Agenda

Tuesday, January 14, 2019
12:00 pm – 2:00 pm (ET)

To join with teleconference capabilities: <https://nasem.zoom.us/j/536204219>

Or join via telephone: +1-888-475-4499 or +1-877-853-5257

Meeting ID: 536 204 219

Session Objectives: To hear perspectives from representatives of 503B compounding facilities on the safety, effectiveness, and clinical utility of compounded bioidentical hormone replacement therapy. To gather additional data on the testing and analytics of compounded bioidentical hormone replacement therapy.

12:00 p.m. Introductions

LEIGH MILES JACKSON, PhD
Study Director, Board on Health Sciences Policy
Health and Medicine Division

DONALD MATTISON, MD
Committee Chair

RUTH PARKER, MD
Committee Vice-Chair

12:05 p.m. Perspectives from Invited Speakers

RACHEL PONTIKES, JD
Partner
Reed Smith LLP

ANGELA DEROSA, DO, MBA
Medical Director
Belmar Pharmacy & Belmar Select Outsourcing

DOUG CAMMANN, RPH
Vice President of Operations
AnazaoHealth Corporation

DONALD PRENTISS
President of Operations
Carie Boyd's Prescription Shop

THOMAS C. KUPIEC, PHD

President/CEO

ARL BioPharma, Inc., DNA Solutions, Inc., The Kupiec Group, LLC

1:20 p.m. **Q&A and Discussion (moderated by committee members)**

1:40 p.m. **Public Comments**

2:00 p.m. **ADJOURN**